Copper-binding tripeptide. Modulates wound healing genes, collagen synthesis, and antioxidant response.
Glycyl-L-histidyl-L-lysine bound to Cu(II). Modulates ~4,000 human genes by some transcriptomic analyses; well-studied in dermatology and wound healing. Mechanism on hair follicles and skin remodeling is robust; orthopedic claims are weaker.
Cosmetic-grade formulations vary widely in actual peptide content. Injectable use is research-grey in the US.
Bound to Cu²⁺ for activity.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Endogenous tripeptide-copper complex with documented effects on skin remodeling, antioxidant tone, and gene expression (~4000 gene-expression changes reported). Pickart lab argues for systemic anti-aging utility beyond cosmetic skin applications.
B-tier mostly for skin/hair/aesthetics — "in person I've seen the effects." Hedges on more research for an A or S tier. Notes injectable form is not FDA-approved yet (now scheduled for PCAC review Feb 2027).
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 1-3 mg · daily topical or subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Topical/cosmetic GHK-Cu widely available. Injectable form pending PCAC review Feb 2027.
As of 2026-04Research-grey injectable range.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin · Semaglutide · Tirzepatide
Houston-based 503A compounding pharmacy, one of the largest in the US peptide compounding market.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin
One of the most consistently recommended vendors on r/Peptides since the Peptide Sciences shutdown (March 2026). Third-party COA published per batch. HPLC purity ≥99%.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Long-established US vendor (7+ years). Broad catalog including GHRPs, GHRHs, and cognitive peptides. Third-party HPLC and mass-spec COA per batch. Active Finnrick Analytics coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Newer vendor with fast turnaround and competitive pricing. Third-party COA on all products. Building Finnrick coverage. Frequently recommended post-Peptide Sciences shutdown.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Established vendor with multi-year community track record. Offers peptide blends (Wolverine Stack, etc.) alongside singles. Third-party COA available on request.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Known for above-average catalog depth, including harder-to-find compounds (SS-31, humanin, Foxo4-DRI). Third-party HPLC published. Active Finnrick coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Clean storefront, competitive pricing, strong community mentions. Third-party COA on most products. Ships to US with fast turnaround.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Injectable: FDA Cat. 2 removed Apr 2026 — PCAC review Feb 2027. Topical: cosmetic.
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.
COFEPRIS regulates Mexican farmacias magistrales (compounding pharmacies) under different rules than the US 503A bulks-list framework. Several Mexican compounding pharmacies prepare BPC-157, TB-500, CJC-1295/Ipamorelin, Tesamorelin, and GHK-Cu without the FDA Category 2 ban that has constrained US compounding since 2023.